Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.
Fiche publication
Date publication
juillet 2017
Journal
Cancer biomarkers : section A of Disease markers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ENTZ-WERLE Natacha
Tous les auteurs :
Quillien V, Lavenu A, Ducray F, Meyronet D, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D
Lien Pubmed
Résumé
Pyrosequencing is recognized as a strong technique to analyze the MGMT status of glioblastoma patients. The most commonly used assay, quantifies the methylation levels of CpGs 74 to 78. A more recent CE-marked In Vitro Diagnostic Medical Device (CE-IVD) assay, Therascreen, analyzes CpGs 76-79.
Mots clés
CE-IVD kit, Glioblastoma, MGMT methylation, pyrosequencing
Référence
Cancer Biomark. 2017 Jul;: